BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34001035)

  • 21. Adjuvant radiotherapy for pancreatic cancer is associated with a survival benefit primarily in stage IIB patients.
    Moody JS; Sawrie SM; Kozak KR; Plastaras JP; Howard G; Bonner JA
    J Gastroenterol; 2009; 44(1):84-91. PubMed ID: 19159077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
    Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
    J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival benefits of postoperative radiotherapy in patients with cT
    Yang J; Zhao J; Chang H; Yan L; Zhang J; Liu H; Ning P
    BMC Womens Health; 2024 Jun; 24(1):324. PubMed ID: 38834997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagent Neoadjuvant Chemotherapy in the Modern Era.
    Hue JJ; Dorth J; Sugumar K; Hardacre JM; Ammori JB; Rothermel LD; Saltzman J; Mohamed A; Selfridge JE; Bajor D; Winter JM; Ocuin LM
    Am Surg; 2021 Sep; 87(9):1386-1395. PubMed ID: 34382877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival.
    Poleszczuk J; Luddy K; Chen L; Lee JK; Harrison LB; Czerniecki BJ; Soliman H; Enderling H
    Breast Cancer Res; 2017 Jun; 19(1):75. PubMed ID: 28666457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cancer.
    Davila JA; Chiao EY; Hasche JC; Petersen NJ; McGlynn KA; Shaib YH
    Pancreas; 2009 Jan; 38(1):e18-25. PubMed ID: 18797424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pancreatectomy predicts improved survival for pancreatic adenocarcinoma: results of an instrumental variable analysis.
    McDowell BD; Chapman CG; Smith BJ; Button AM; Chrischilles EA; Mezhir JJ
    Ann Surg; 2015 Apr; 261(4):740-5. PubMed ID: 24979599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The survival effect of neoadjuvant therapy and neoadjuvant plus adjuvant therapy on pancreatic ductal adenocarcinoma patients with different TNM stages: a propensity score matching analysis based on the SEER database.
    Hu H; Xu Y; Zhang Q; Gao Y; Wu Z
    Expert Rev Anticancer Ther; 2024 Jun; 24(6):467-476. PubMed ID: 38656796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
    Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
    Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.
    Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK
    Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effects of neoadjuvant radiotherapy, adjuvant radiotherapy, and chemotherapy-only on survival of locally advanced non-small cell lung Cancer undergoing surgery: a propensity-matched analysis.
    Wang X; Yin C; Su S; Li X; Wang C; Zhang C; Liu M
    BMC Cancer; 2018 Nov; 18(1):1067. PubMed ID: 30400782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma.
    Jiang W; Haque W; Verma V; Butler EB; Teh BS
    Acta Oncol; 2019 Sep; 58(9):1259-1266. PubMed ID: 31237185
    [No Abstract]   [Full Text] [Related]  

  • 34. Trends in utilization of neoadjuvant therapy and short-term outcomes in resected pancreatic cancer.
    Mirkin KA; Hollenbeak CS; Gusani NJ; Wong J
    Am J Surg; 2017 Jul; 214(1):80-88. PubMed ID: 27816199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant
    Hashmi A; Kozick Z; Fluck M; Hunsinger MA; Wild J; Arora TK; Shabahang MM; Blansfield JA
    Am Surg; 2018 Sep; 84(9):1439-1445. PubMed ID: 30268172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis.
    Stumpf PK; Amini A; Jones BL; Koshy M; Sher DJ; Lieu CH; Schefter TE; Goodman KA; Rusthoven CG
    Cancer; 2017 Sep; 123(17):3402-3409. PubMed ID: 28513823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal timing and treatment strategy for pancreatic cancer.
    Gamboa AC; Rupji M; Switchenko JM; Lee RM; Turgeon MK; Meyer BI; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM
    J Surg Oncol; 2020 Sep; 122(3):457-468. PubMed ID: 32470166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
    Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F
    Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study.
    de Geus SWL; Kasumova GG; Eskander MF; Ng SC; Kent TS; James Moser A; Vahrmeijer AL; Callery MP; Tseng JF
    J Gastrointest Surg; 2018 Feb; 22(2):214-225. PubMed ID: 29235000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.